Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial

Montillo, MarcoIllés, ÁrpádRobak, TadeuszPristupa, Alexander S.Wach, MalgorzataEgyed, MiklósDelgado, JulioJurczak, WojciechMorschhauser, FranckSchuh, AnnaEradat, HerbertShreay, SanatanBarrientos, Jacqueline C.Zelenetz, Andrew D.2019-12-122019-12-122019Health and Quality of Life Outcomes. -17 : 1 (2019) p. 1-11. -Health Qual. Life Outcomes. - 1477-7525. - 1477-75251477-7525http://hdl.handle.net/2437/277296Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trialidegen nyelvű folyóiratközlemény külföldi lapbanopen access journalhttp://webpac.lib.unideb.hu:8082/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM082544OrvostudományokKlinikai orvostudományokhttps://hqlo.biomedcentral.com/articles/10.1186/s12955-019-1232-8http://dx.doi.org/10.1186/s12955-019-1232-82020-02-27